{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T17:11:28Z","timestamp":1788628288024,"version":"build-2803163510"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Invasive fungal infections (IFIs) are severe and difficult-to-treat infections affecting immunocompromised patients. Antifungal drug penetration at the site of infection is critical for outcome and may be difficult to achieve. Data about antifungal drug distribution in infected human tissues under real circumstances of IFI are scarce.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Multiple samples were obtained from soft tissue abscesses of a lung transplant patient with Candida albicans invasive candidiasis who underwent recurrent procedures of drainage, while receiving different consecutive courses of antifungal therapy [itraconazole (ITC), fluconazole, caspofungin]. Antifungal drug concentrations were measured simultaneously at the site of infection (surrounding inflammatory tissue and fluid content of the abscess) and in plasma for calculation of the tissue\/plasma ratio (R). The concentration within the infected tissue was interpreted as appropriate if it was equal or superior to the MIC of the causal pathogen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 30 tissue samples were collected for measurements of ITC (n\u200a=\u200a12), fluconazole (n\u200a=\u200a17) and caspofungin (n\u200a=\u200a1). Variable concentrations were observed in the surrounding tissue of the lesions with median R of 2.79 (range 0.51\u201315.9) for ITC and 0.94 (0.21\u20131.37) for fluconazole. Concentrations ranges within the fluid content of the abscesses were 0.39\u20131.83 for ITC, 0.66\u20131.02 for fluconazole and 0.23 (single value) for caspofungin. The pharmacodynamic target (tissue concentration\u200a\u2265\u200aMIC) was achieved in all samples for all three antifungal drugs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This unique dataset of antifungal drug penetration in infected human soft tissue abscesses suggests that ITC, fluconazole and caspofungin could achieve appropriate concentrations in soft tissue abscesses.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae162","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T14:45:00Z","timestamp":1716561900000},"page":"1668-1672","source":"Crossref","is-referenced-by-count":4,"title":["Antifungal drug penetration in soft tissue abscesses: a comparative analysis"],"prefix":"10.1093","volume":"79","author":[{"given":"Alicia","family":"Cancela Costa","sequence":"first","affiliation":[{"name":"Service of Infectious Diseases, Department of Medicine, Lausanne University Hospital and University of Lausanne , Lausanne , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Kritikos","sequence":"additional","affiliation":[{"name":"Service of Infectious Diseases, Department of Medicine, Lausanne University Hospital and University of Lausanne , Lausanne , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Glampedakis","sequence":"additional","affiliation":[{"name":"Service of Infectious Diseases, Department of Medicine, Lausanne University Hospital and University of Lausanne , Lausanne , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Da Silva Pereira Clara","sequence":"additional","affiliation":[{"name":"Service and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne , Lausanne , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Schaller","sequence":"additional","affiliation":[{"name":"Service and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne , Lausanne , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mercier","sequence":"additional","affiliation":[{"name":"Service and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne , Lausanne , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Strasser","sequence":"additional","affiliation":[{"name":"Department of Orthopedics and Traumatology, Lausanne University Hospital and University of Lausanne , Lausanne , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zisis","family":"Balmpouzis","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Lausanne University Hospital and University of Lausanne , Lausanne , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Koutsokera","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Lausanne University Hospital and University of Lausanne , Lausanne , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7607-0943","authenticated-orcid":false,"given":"Oriol","family":"Manuel","sequence":"additional","affiliation":[{"name":"Service of Infectious Diseases, Department of Medicine, Lausanne University Hospital and University of Lausanne , Lausanne , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0639-5536","authenticated-orcid":false,"given":"Thierry","family":"Buclin","sequence":"additional","affiliation":[{"name":"Service and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne , Lausanne , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9840-1325","authenticated-orcid":false,"given":"Laurent Arthur","family":"Decosterd","sequence":"additional","affiliation":[{"name":"Service and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne , Lausanne , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1023-5597","authenticated-orcid":false,"given":"Frederic","family":"Lamoth","sequence":"additional","affiliation":[{"name":"Service of Infectious Diseases, Department of Medicine, Lausanne University Hospital and University of Lausanne , Lausanne , Switzerland"},{"name":"Institute of Microbiology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne , Lausanne , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"2024070109565949900_dkae162-B1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/CMR.00046-13","article-title":"Tissue penetration of antifungal agents","volume":"27","author":"Felton","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"2024070109565949900_dkae162-B2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"2024070109565949900_dkae162-B3","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2024070109565949900_dkae162-B4","doi-asserted-by":"crossref","first-page":"e01184-19","DOI":"10.1128\/AAC.01184-19","article-title":"Low central nervous system posaconazole concentrations during cerebral phaeohyphomycosis","volume":"63","author":"Barde","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024070109565949900_dkae162-B5","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1093\/jac\/dkv173","article-title":"Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis","volume":"70","author":"Grau","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2024070109565949900_dkae162-B6","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jac\/dkz050","article-title":"Isavuconazole brain penetration in cerebral aspergillosis","volume":"74","author":"Lamoth","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024070109565949900_dkae162-B7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.4103\/1735-5362.301335","article-title":"Bayesian estimation of pharmacokinetic parameters: an important component to include in the teaching of clinical pharmacokinetics and therapeutic drug monitoring","volume":"15","author":"Brocks","year":"2020","journal-title":"Res Pharm Sci"},{"key":"2024070109565949900_dkae162-B8","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2024070109565949900_dkae162-B9","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1592\/phco.23.5.592.32202","article-title":"Enteral fluconazole population pharmacokinetics in patients in the surgical intensive care unit","volume":"23","author":"Rajagopalan","year":"2003","journal-title":"Pharmacotherapy"},{"key":"2024070109565949900_dkae162-B10","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1128\/AAC.01912-12","article-title":"Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis","volume":"57","author":"W\u00fcrthwein","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2024070109565949900_dkae162-B11","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1128\/AAC.00404-10","article-title":"Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin","volume":"54","author":"Decosterd","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2024070109565949900_dkae162-B12","author":"CLSI"},{"key":"2024070109565949900_dkae162-B13","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1128\/AAC.41.11.2339","article-title":"Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872)","volume":"41","author":"Hajdu","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2024070109565949900_dkae162-B14","doi-asserted-by":"crossref","first-page":"e01292-17","DOI":"10.1128\/AAC.01292-17","article-title":"Tissue distribution and elimination of isavuconazole following single and repeat oral-dose administration of isavuconazonium sulfate to rats","volume":"61","author":"Schmitt-Hoffmann","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024070109565949900_dkae162-B15","doi-asserted-by":"crossref","first-page":"e01009-17","DOI":"10.1128\/AAC.01009-17","article-title":"Unraveling drug penetration of echinocandin antifungals at the site of infection in an intra-abdominal abscess model","volume":"61","author":"Zhao","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024070109565949900_dkae162-B16","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.amjsurg.2010.09.010","article-title":"Impact of evaluating antibiotic concentrations in abdominal abscesses percutaneously drained","volume":"201","author":"Zimmerman","year":"2011","journal-title":"Am J Surg"},{"key":"2024070109565949900_dkae162-B17","doi-asserted-by":"crossref","first-page":"e02474-18","DOI":"10.1128\/AAC.02474-18","article-title":"Isavuconazole diffusion in infected human brain","volume":"63","author":"Rouzaud","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 3","key":"2024070109565949900_dkae162-B18","doi-asserted-by":"crossref","first-page":"S318","DOI":"10.1093\/clinids\/12.Supplement_3.S318","article-title":"Pharmacokinetics and tissue penetration of fluconazole in humans","volume":"12","author":"Brammer","year":"1990","journal-title":"Rev Infect Dis"},{"key":"2024070109565949900_dkae162-B19","doi-asserted-by":"crossref","first-page":"e01034-17","DOI":"10.1128\/AAC.01034-17","article-title":"Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi","volume":"61","author":"Desai","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024070109565949900_dkae162-B20","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1128\/AAC.46.3.739-745.2002","article-title":"Single- and multiple-dose pharmacokinetics of caspofungin in healthy men","volume":"46","author":"Stone","year":"2002","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/7\/1668\/58375096\/dkae162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/7\/1668\/58375096\/dkae162.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T09:57:22Z","timestamp":1719827842000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/7\/1668\/7681680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,5,24]]},"published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae162","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,5,24]]}}}